REGENICIN INC

As of March 31, 2023, REGENICIN INC carries a market capitalization of 214,876.27, placing it among publicly traded companies globally. Its enterprise value stands at -11.00M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2023, REGENICIN INC has 153.48M shares outstanding.

These figures are as of March 31, 2023.

As of March 31, 2023, REGENICIN INC maintains a current ratio of 0.66, meaning it holds 0.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -10.35, indicating conservative leverage, while an interest coverage ratio of -24.21 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended March 31, 2023. Return on assets (ROA) is negative at -15.72, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 3.00, a quick read on workforce productivity versus industry peers.

As of the close on September 29, 2026, REGENICIN INC's stock has declined approximately 99.00% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.01.

Over the twelve months ended March 31, 2023, REGENICIN INC generated - - in revenue and converted that into -932,437.00 in net income, yielding earnings per share of -0.01. EBITDA reached -894,589.00, while operating income came in at -894,589.00.

As of March 31, 2023, REGENICIN INC holds 11.86M in cash and equivalents against 642,918.00 in total debt, resulting in a net debt position of -10.24M. Total book value stands at -6.21M, with working capital of -6.21M providing operational flexibility.

REGENICIN INC produced -700,219.00 in operating cash flow over the twelve months ended March 31, 2023.

These figures cover the twelve months ended March 31, 2023. The dividend payout ratio of 5.37 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -325.87: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 444.45, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to REGENICIN INC shareholders.

REGENICIN INC's most recent stock split took place on August 18, 2010 with a 1:34 split ratio.

As of March 31, 2023, REGENICIN INC has an Altman Z-Score of -2.83, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.